Changes in oral antidiabetic prescriptions and improved glycemic control during the years 2002–2011 in J apan ( JDDM 32)

Aims/IntroductionSix kinds of oral antidiabetic drugs (OADs), including the new dipeptidyl peptidase 4 (DPP‐4) inhibitors, are available. The present study aimed to define trends within the prescribing patterns of OADs, as well as changes in glycemic control in Japan over a 10‐year period from 2002...

Full description

Saved in:
Bibliographic Details
Published in:Journal of diabetes investigation 2014-09, Vol.5 (5), p.581-587
Main Authors: Oishi, Mariko, Yamazaki, Katsuya, Okuguchi, Fuminobu, Sugimoto, Hidekatsu, Kanatsuka, Azuma, Kashiwagi, Atsunori
Format: Article
Language:English
Subjects:
Antidiabetics
Diabetes
Diabetes mellitus
Diabetes mellitus (non-insulin dependent)
Dipeptidyl-peptidase IV
Drug dosages
Ethics
Hemoglobin
Insulin
Peptidase
Software
Trends
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aims/IntroductionSix kinds of oral antidiabetic drugs (OADs), including the new dipeptidyl peptidase 4 (DPP‐4) inhibitors, are available. The present study aimed to define trends within the prescribing patterns of OADs, as well as changes in glycemic control in Japan over a 10‐year period from 2002 to 2011.Materials and MethodsWe carried out a cross‐sectional study using data of type 2 diabetes mellitus patients from 24 clinics for 2002, 2005, 2008 and 2011. OAD use was analyzed combined with clinical data.ResultsSulfonylureas (SUs) were the most commonly used OAD, but their use for monotherapy markedly decreased over the study period. Biguanides (BGs) were the second most commonly used OAD, and their prescribing rate increased both for mono‐ and combination therapy. DPP‐4 inhibitors (DPP‐4I), released in 2009, were the third most commonly prescribed OAD in 2011 both for mono‐ and combination therapy. Among combination therapies, two OADs were mostly prescribed, but the use of three OADs and four OADs in 2011 was two‐ and 14.8‐fold those in 2002. These trends were accompanied by an improvement in average glycated hemoglobin from 7.5 ± 1.2% in 2002 to 7.1 ± 0.9% in 2011.ConclusionsThe OAD prescribing trend has moved away from monotherapy with SUs and toward combination therapies to achieve better glycemic control. Increased use of BGs and DPP‐4I was predominant in 2011. These trends were accompanied by an improvement of the glycated hemoglobin level.
ISSN:2040-1116
2040-1124
DOI:10.1111/jdi.12183